Anjalee Khemlani of Yahoo Finance analyzes the latest data on the effectiveness of the Novavax vaccine after tests in the United Kingdom and South Africa
Video transcription
ADAM SHAPIRO: So there is breaking news with Novavax. What do you have, Anjalee?
ANJALEE KHEMLANI: Correct, Adam. We just learned that Novavax has released its final results on the effectiveness of its COVID-19 vaccine in studies in the UK and South Africa, and this is showing really high efficacy rates. We obtained 96.4% in the United Kingdom with the original strain of COVID-19, as well as 86% against the strain of the United Kingdom, which is the B117 that we know to be a concern here in the USA. And it is highly transferable, as well as a total of 89% from the UK.
Moving to South Africa now, that is 55% of non-participants in HIV. This is showing some very strong results, and it is on the same level as what we saw. Novavax is supposed to be one of the most effective compared to the others. But we cannot necessarily make a comparison equivalent to, say, Pfizer and Moderna which achieved similar results here in the United States.
But we saw lower results, you know, from Johnson & Johnson when you looked at the kind of global effect. And this is important because we know that Novavax is trying to use some of the world’s data to get approval here in the USA.
ADAM SHAPIRO: And it is important to note that Novavax shares closed with an increase of almost 9%. And now, after hours, they are going up about 7% with that news. Anjalee, thank you.